Lorazepam
Nodding Syndrome
Makerere UniversitySmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Nodding Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vitamin B6 Centers for Disease Control and Prevention | Phase 2 | CCC |
Valproic Acid Centers for Disease Control and Prevention | Phase 2 | CCC |
PHENYTOIN Centers for Disease Control and Prevention | Phase 2 | CCC |
Same molecule, other indications
Lorazepam is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →